Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 4, 1997, Pages 417-425

  Kazierad, David J ^a   Martin, David E ^b   Blum, Robert A ^b   Tenero, David M ^b   Ilson, Bernard ^b   Boike, Steven C ^b   Etheredge, Rickey ^b   Jorkasky, Diane K ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPROSARTAN; FLUCONAZOLE; LOSARTAN; LOSARTAN POTASSIUM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ACRYLATES; ADULT; ANTIFUNGAL AGENTS; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG ADMINISTRATION SCHEDULE; FLUCONAZOLE; HUMANS; IMIDAZOLES; LOSARTAN; MALE; MIDDLE AGED; REFERENCE VALUES; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TETRAZOLES; THIOPHENES; TIME FACTORS;

EID: 0030724427     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90120-X     Document Type: Article

References (20)

1. Edwards RM, Aiyar N, Ohlstein EH, Weidley EF, Griffin E, Ezekiel M, et al. Pharmacological characterization of the non-peptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther 1992;260:175-81.
2. Cox PJ, Bush BD, Gorycki PD, Kuo GY, Kenworthy D, Law DW, et al. The metabolic fate of eprosartan in healthy subjects. Exp Toxicol Pathol 1996;48:340-1.
3. Merck & Co. Cozaar tablets. In: Physicians' Desk Reference. 50th ed. Oradell, NJ: Medical Economics Company; 1996. p. 1628-30.
4. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995; 58:641-64.
5. Stearns RA, Chakravarty PK, Chen R, Chiu SH. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995;23:207-15.
6. McCrea JB, Low MW, Furtek CI, Ritter BA, Carides A, Waldman SA, et al. Ketoconazole does not effect the systemic conversion of losartan to E-3174. Clin Pharmacol Ther 1996;59:A169.
7. Hargreaves JA, Jezequel S, Houston JB. Effect of azole antifungals on human microsomal metabolism of diclofenac and midazolam. Br J Clin Pharmacol 1994;38:175P.
8. Blum RA, Wilton JH, Hilligoss DM, Gardner MJ, Henry EB, Harrison NJ, et al. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 1991;49:420-5.
9. Black DJ, Kunze KL, Wienkers LC, Gidal BE, Seaton TL, McDonnell ND, et al. Warfarin-fluconazole II: a metabolically based drug interaction - in vivo studies. Drug Metab Dispos 1996;24:422-8.
10. Goldstein JA, de Morals SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994;4:285-99.
11. Lundberg DE, Person CR, Know S, Cyronak M. Determination of SK&F 108566 in human plasma by solid phase extraction cleanup and reversed-phased high-pressure liquid chromatography. J Chromatogr [in press].
12. Furtek CI, Lo M. Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high performance liquid chromatography. J Chromatogr 1992;573:295-301.
13. Steinjans VW, Diletti E. Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals. Eur J Clin Pharmacol 1983;24:127-36.
14. Munafo A, Christen Y, Nussberger J, Shum LY, Borland M, Lee RJ, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992;51:513-21.
15. Spielberg S, McCrea J, Cribb A, Rushmore T, Waldman S, Bjornsson T, et al. A mutation in CYP2C9 is responsible for decreased metabolism of losartan. Clin Pharmacol Ther 1996;59:A215.
16. Delfa IL, Zhu QM, Mo Z, Blaschke TF. Fluconazole is a potent inhibitor of antipyrine metabolism in vivo in mice. Drug Metab Dispos 1989;17:49-53.
17. Purba HS, Back DJ. Effect of fluconazole (UK-49,858) on antipyrine metabolism. Br J Clin Pharmacol 1986;21:603P.
18. Kruger HU, Schuler U, Zimmerman R, Ehninger G. Absence of significant interaction of fluconazole with cyclosporin. J Antimicrob Chemother 1989;24: 781-6.
19. Graves NM, Matas AJ, Hilligoss DM, Canafax DM. Fluconazole/cyclosporine interaction. Clin Pharmacol Ther 1990;47:A208.
20. Goldberg MR, Lo MW, Deutsch PJ, Wilson SE, Mc-Williams EJ, McCrea JB. Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174. Clin Pharmacol Ther 1996;59:268-74.